14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $35.67 $42.91 Friday, 3rd May 2024 CLDX stock ended at $42.56. This is 4.16% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 3.80% from a day low at $41.34 to a day high of $42.91.
90 days $35.03 $53.18
52 weeks $22.11 $53.18

Historical Celldex Therapeutics prices

Date Open High Low Close Volume
Feb 23, 2023 $42.17 $42.17 $40.85 $41.50 379 736
Feb 22, 2023 $42.29 $42.99 $41.18 $41.75 250 135
Feb 21, 2023 $42.41 $43.07 $41.58 $42.07 322 071
Feb 17, 2023 $42.50 $43.45 $41.95 $43.02 315 839
Feb 16, 2023 $42.24 $42.79 $41.90 $42.34 270 187
Feb 15, 2023 $42.31 $43.17 $41.61 $42.88 277 369
Feb 14, 2023 $41.88 $43.07 $41.45 $42.58 177 487
Feb 13, 2023 $43.70 $43.70 $42.11 $42.17 227 685
Feb 10, 2023 $43.16 $43.79 $42.83 $43.57 203 093
Feb 09, 2023 $42.37 $43.62 $41.80 $43.32 225 566
Feb 08, 2023 $45.53 $45.53 $41.98 $42.34 530 159
Feb 07, 2023 $46.34 $46.41 $45.19 $45.90 571 495
Feb 06, 2023 $46.00 $47.27 $44.78 $46.14 332 580
Feb 03, 2023 $44.44 $46.27 $44.44 $46.09 345 816
Feb 02, 2023 $43.81 $45.01 $42.09 $44.98 448 126
Feb 01, 2023 $44.06 $44.51 $42.91 $43.71 480 069
Jan 31, 2023 $44.24 $45.00 $43.80 $44.06 389 272
Jan 30, 2023 $45.87 $46.24 $43.82 $44.16 326 193
Jan 27, 2023 $45.71 $46.94 $45.37 $46.25 225 493
Jan 26, 2023 $46.67 $46.84 $45.34 $45.83 239 009
Jan 25, 2023 $46.35 $46.80 $44.91 $46.50 326 307
Jan 24, 2023 $46.39 $47.59 $46.08 $46.52 516 399
Jan 23, 2023 $46.62 $47.17 $45.79 $46.59 327 927
Jan 20, 2023 $47.23 $47.35 $46.00 $46.61 362 000
Jan 19, 2023 $46.39 $47.50 $46.25 $46.46 282 141
Click to get the best stock tips daily for free!

About Celldex Therapeutics

Celldex Therapeutics Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity... CLDX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT